Although highly effective lipid-lowering drugs are available, cardiovascular disease (CVD) remains the numberone cause of death in developed countries 1 , and there remains a clear and unmet need for the identi fication of new therapeutic targets for CVD. Genetic contributions have a strong role in disease pathogenesis, yet large-scale studies revealed that genetic variation can account for only a minor component (<20%) of the risk of developing CVD 2, 3 . Thus, environmental factors have a prominent role in CVD pathogenesis, and it has long been known that diet, our major environment exposure, is a major contributor to the risk of developing CVD 4 . Resident microbial communities in the intestinal tract represent a key 'metabolic filter' of our diet as they can convert common nutrients into metabolites, some of which have been linked to CVD 5, 6 . Indeed, both epidemiological and animal model studies have provided strong support for the idea that the interplay between microorganisms and the host has a contributory role in atherosclerotic CVD [6] [7] [8] . Chronic infection with pathogenic bacteria and intestinal dysbiosis have been associated with the progression of CVD [9] [10] [11] [12] [13] [14] [15] [16] [17] . Bacterial molecular patterns can directly engage host pattern recognition receptors (PRRs) in the intestine but also in the vasculature 5 , promoting chronic inflammatory processes in the host. In addition to the direct stimulation of host immunity, the host microbiota can produce a wide variety of small-molecule metabolites that are sensed by host receptor systems to affect CVD pathogenesis in a manner that does not require direct microorganism-host interactions. In fact, recent evidence suggests that the susceptibility to both atherosclerosis 7 and thrombosis 8 can be transmitted via gut microbial transplantation in mice. Research over the past decade has uncovered several key microbial metabolites, such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs) and secondary bile acids that uniquely affect the progression of CVD. Although large antibiotic intervention trials have not shown clear bene fit in CVD [18] [19] [20] , drug discovery is entering a new and exciting phase where targeting gut microbial metabolites represents a new tractable therapeutic strategy.
In this Review, we discuss the relevant transmissible microbial communities and taxa that are associated with, and microorganism-derived metabolites directly involved with, CVD pathogenesis. With the major technological advances in microbial profiling methods and other 'omic' analytic platforms, we are now uniquely positioned to discover candidate microorganisms and their derived metabolites of relevance to CVD-related phenotypes and to pursue studies aimed at understanding mechanisms by which our microbial inhabitants impact human disease. We review microorganism-driven pathways that were reported to have an impact on CVD pathogenesis and discuss how gut microorganism-targeted therapeutics hold untapped promise as new therapies for the prevention and/or treatment of CVD.
Microorganism-associated molecular patterns
It is now well appreciated that diverse microbial communities reside within the intestinal tract, on the skin surface and on nearly every exposed surface of the human body Although still controversial, there is also a growing body of literature suggesting that increased permeability of oral and intestinal epithelial barriers enables a small number of bacteria to enter into the systemic circulation, where they can ultimately enter into host tissues to promote disease 9, 21, 22 . Whether residing in or on exposed surfaces, or when they access the systemic circulation, bacteria can directly engage the innate immune system not only to elicit the appropriate bactericidal responses but also to regulate the host metabolism and inflammatory pathways relevant to CVD. This type of micro organismhost crosstalk is driven by direct interaction of microorganism-associated molecular patterns (MAMPs) and host PRRs (FIG. 1) . There are now a number of examples linking MAMP-PRR-driven signalling pathways to heart disease and, in fact, chronic infections. In addition, evidence of prior exposure to certain bacterial pathogens has been associated with increased CVD risk [9] [10] [11] [12] [13] [14] [15] [16] [17] . Several recent studies have analysed microbiota communities in human oral, gut and atherosclerotic plaques from individuals with established atherosclerosis and have found a reproducible correlation between CVD and bacterial pathogens, including Chlamydia pneumoniae, Porphyromonas gingivalis, Helicobacter pylori and Aggregatibacter actinomycetemcomitans [10] [11] [12] [13] . Importantly, some of these bacteria have been found in the intestinal tract, as expected, but also within atherosclerotic plaques [11] [12] [13] , which indicates the possibility of engagement of PRRs in highly distinct microenvironments. In a metagenome-wide association study for atherosclerosis, it was recently reported that Collinsella spp. are enriched in subjects with atherosclerosis, while Eubacterium spp. and Roseburia spp. are more abundant among healthy controls 14 . Whether these associations are causally linked to disease pathogenesis or are driven by the presence of disease or disease-associated comorbidities and/or therapeutics remains to be determined.
Initially described in the Helsinki Heart Study, the common microbial pathogen C. pneumoniae has repeatedly been associated with CVD [15] [16] [17] [18] [19] [20] . In addition, C. pneumoniae has been shown in vitro to elicit cell autonomous pro-inflammatory effects in isolated macrophages, endothelial cells and smooth muscle cells, which would be consistent with a link to atherosclerotic CVD 16, 17 . However, primary infection with C. pneumoniae has inconsistently altered atherosclerosis phenotypes in mouse models, and antibiotic treatments effective at treating C. pneumoniae are ineffective in clinical studies, leaving a causal role for the bacteria in disease patho genesis still a matter of debate [18] [19] [20] [21] [22] [23] . More evidence for a bacterial-CVD link was provided from studies investi gating the pathogen P. gingivalis, which has been investi gated because of associations between periodontal disease and CVD risk [24] [25] [26] [27] [28] [29] . Either oral or systemic infection with P. gingivalis accelerates atherosclerosis in animal models, in part by promoting macrophage foam cell formation and inducing platelet aggregration [24] [25] [26] [27] [28] [29] . Also, there may be a link between H. pylori infection and CVD risk [30] [31] [32] . However, careful primary infection studies in mouse models of atherosclerosis have yielded conflicting results [30] [31] [32] . Collectively, there are a number of reports suggesting that pathogenic bacteria are causally linked to atherosclerotic CVD. However, whether CVD can be viewed as an infectious disease is still matter of intense debate because, as noted above, a number of large, randomized, prospective human antibiotic and antiviral trials have failed to show any benefit of treatment or prophylaxis therapy in CVD or mortality [18] [19] [20] [21] [22] [23] . Even with the disappointing news with large antibiotic trials, there is ever-expanding evidence that host PRRs are important regulators of CVD pathogenesis. For instance, SNPs in the host peptidoglycan receptor NOD1 (nucleotide-binding oligomerization domain-containing protein 1) are linked to early-onset coronary heart disease 33 , and Nod1 -/-mice are protected against atherosclerosis on an apolipoprotein-E-null (Apoe -/-) background, which is a commonly used mouse model of atherosclerosis driven by elevated cholesterol levels in the form of circulating remnant lipoproteins 34 . The heterodimeric Nature Reviews | Microbiology NOD1   TLR1-TLR2   TLR2-TLR6  TLR  TLR4 or CD14
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Metabolite endotoxaemia systemic bacterial translocation Figure 1 | Direct engagement of pattern recognition receptors by microorganismassociated molecular patterns driving cardiovascular disease. Microorganismassociated molecular patterns (MAMPs) can promote cardiovascular disease (CVD) via the direct engagement of host pattern recognition receptors (PRRs), promoting chronic inflammatory processes in the host. In the context of cardiovascular disease, dysbiosis in both the oral and gut microbiome can elicit local MAMP-PRR signalling within those microenvironments (not shown). In addition, systemic bacterial translocation can promote CVD by MAMP-PRR signalling in distant sites, including the liver and artery wall. CpG-ODNs, CpG oligodeoxynucleotides; dsRNA, double-stranded RNA; LPS, lipopolysaccharide; NOD1, nucleotide-binding oligomerization domain-containing protein 1; ssRNA, single-stranded RNA; TLR, Toll-like receptor.
Ischaemic stroke
A stroke that occurs when a blood vessel to the brain is blocked by a blood clot.
Metabolome
The complete set of small-molecule chemicals found within a biological sample.
complex of Toll-like receptor 2 (TLR2) and TLR6 is central to sensing bacterial diacylated and triacylated peptides 35, 36 . A recently described SNP in the Tlr6 gene has been linked to left ventricular wall thickening and markers of inflammation 37, 38 , and Tlr2 -/-mice have strikingly reduced atherosclerosis, especially when challenged with synthetic TLR2 agonists 36 . Furthermore, transplantation of bone marrow from mice lacking the double-stranded DNA receptor TLR3 into Ldlr −/− mice, which is a commonly used mouse model of athero sclerosis driven by elevated low-density lipoprotein cholesterol levels, results in reduced athero sclerosis burden 39 . Among all of the CVD-associated MAMP-PRR pathways, the lipopolysaccharide receptor TLR4 has been most thoroughly investigated [40] [41] [42] [43] [44] . Many TLR4 SNPs have been reported, some with no association, some with increased association and some with decreased association with CVD risks [40] [41] [42] [43] [44] . However, genetic deficiency of TLR4 in either Ldlr −/− or Apoe −/− mice is reported to reduce atherosclerotic burden [41] [42] [43] . Importantly, many other nonbacterial 'endogenous' TLR4 agonists such as oxidized low-density lipo proteins 42 , saturated fatty acids 43 and high mobility group protein B1 (HMGB1) 44 have been shown to promote athero sclerosis progression. Additionally, an SNP in TLR7, a receptor for single-stranded RNA, has been linked to ischaemic stroke 45 ; however, intriguingly, TLR7 deficiency in an Apoe −/− background worsens atherosclerosis 46 . In a simi lar fashion, mice lacking the unmethylated CpG DNA receptor TLR9 in an Apoe −/− background have exacerbated atherosclerosis 47 . Collectively, there is little doubt that activation of a number of host MAMP-PRR pathways can affect atherosclerosis progression. However, it remains doubtful that either activating or inhibiting PRRs are a viable option because of the central role of these receptors in innate immunity.
Microbial metabolites in cardiovascular disease
In addition to surface antigens (MAMPs) on commensal and pathogenic bacteria, gut microorganisms enzymatically produce various metabolites that can act locally in the gut and travel systemically to affect host physiology in healthy and disease states. In fact, our gut micro biome represents a crucial filter of our diet and effectively chemically diversifies each meal we consume. This simple idea that microorganisms themselves, or products secreted from microorganisms, can contribute to disease or improve health, has been bolstered tremendously over the past decade. Recent advances in the fields of untargeted metabolomics in well-characterized clinical cohorts, coupled with mechanistic animal model studies, have been used to discover several human disease-associated gut microbial metabolites. In fact, we now know that there are a large number of circulating metabolites that are derived solely or in part from bacterial metabolism of either dietary nutrients or diet-derived xenobiotics [48] [49] [50] [51] . The rapidly expanding microorganism-dependent metabolome includes many methylamines, polyamines, polysaccharides, SCFAs, secondary bile acids, B vitamins, uraemic toxins, such as p-cresol sulfate and indoxyl sulfate, 4-ethylphenylsulfate and dihydrodigoxin, as well as a long list of xenobiotic-derived metabolites [48] [49] [50] [51] . At this point, several microbial metabolites are recognized, the levels of which are associated with CVD-related phenotypes, but as association does not equal causation, the potential mechanistic participation of these metabolites in CVD remains unclear. A major limitation in progress on mechanistic studies, beyond their laborious nature, is that many of the circulating candidate analytes are yet chemically undefined. Moreover, even for those that are structurally resolved and available for study, we have almost no information about how microorganismgenerated metabolites are sensed, whether it is through dedicated host receptor systems or whether they have non-receptor-mediated mechanisms to affect CVD pathogenesis (for example, as allosteric modifiers).
Currently, there are three main classes of gut microorganism-dependent metabolites that have been linked to CVD risk either in humans or in mouse models: trimethyl amines, SCFAs and secondary bile acids. We focus on the current mechanistic understandings through which these gut microorganism-dependent metabolites signal to the host and affect CVD pathogenesis.
The g ut microorganism-derived metabolite trimethylamine-N-oxide. Since its discovery and first reported link to CVD pathogenesis 52 , the gut microbial co-metabolite TMAO has quickly gained traction as both a biomarker for human CVD risk and a promoter of athero thrombotic diseases [5] [6] [7] [8] 46, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . In fact, numerous human and mouse studies support the notion that the TMAO pathway is one of the first bona fide gut microbiome-centred CVD drug targets 5, 6, 46, . The TMAO pathway is a metaorganismal metabolic pathway whereby nutrients that are present in highfat foods (phosphatidylcholine, choline, l-carnitine and other trimethylamine (TMA)-containing nutrients) can be metabo lized by several distinct gut microbial enzyme complexes (the choline utilization TMA lyase system (CutC/D) 76 and the carnitine Rieske-type oxygenase/reductase system (CntA/B and YeaW/X)) 55 to generate the primary gut microbial metabolite TMA. TMA can be synthesized by the CutC/D, CntA/B or YeaW/X systems, which can utilize multiple substrate sources 55 . TMA then enters the portal circulation and is further metabolized by host enzymes in the liver, called flavin-containing monooxygenases (predominantly the dimethylaniline monooxygenase [N-oxide-forming] 3 (FMO3) isoform), to produce TMAO (FIG. 2) . Several recent reviews have highlighted the clinical relevance and therapeutic potential of the TMAO pathway in CVD 5, 6, 51 ; therefore, these are not discussed in detail here. Briefly, a wealth of human and animal model data support the conclusion that the gut microorganismderived metabo lite TMAO has strong clinical prognostic value and that dietary provision of TMAO can promote athero sclerosis and thrombotic vascular disease in mouse models [5] [6] [7] [8] 46, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . In addition to roles in atherosclerosis and thrombosis, the TMAO pathway has also been associated with other closely linked cardio metabolic diseases in humans, including cardiac hypertrophy, cardiac fibrosis, chronic kidney disease, type 2 diabetes and obesity [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] .
The gut microbiome-driven metabolite TMAO represents a promising gut microbiome-centred drug target 51 
. In fact, with the recent seminal discoveries of the microbial enzymes catalysing the production of TMA 76, 77 , we are now poised to therapeutically intervene in this pathway at the level of gut microbial enzym ology. However, at this point, the molecular mechanisms whereby TMAO promotes atherosclerosis, thrombosis, heart failure, renal dysfunction, insulin resistance and obesity are still being elucidated. This is, in large part, due to the lack of understanding of the molecular sensor for TMAO (that is, the TMAO receptor). Although there is evidence that TMAO can function as an important osmolyte in biological systems 78, 79 , more recent evidence suggests that TMAO can rapidly signal to cells within minutes 8, 80 . In isolated platelets, brief exposures to physiological levels of TMAO can potentiate thrombin-induced calcium release 8 . Likewise, treatment with TMAO in endothelial cells or smooth muscle cells, or direct injection in vivo, was shown to rapidly induce the activation of mitogen-activated protein kinases and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or the upregulation of downstream adhesion proteins on aortic endothelial cells 80 . The kinetics of these TMAO-induced signalling responses strongly suggest that host cells possess a dedicated receptor or sensor system to transduce the TMAO signal to an appropriate cellular response (FIG. 2) . Likewise, elevated TMAO levels are associated with elevated phosphorylation of the protein SMAD3, which is a key effector of transforming growth factor-β (TGFβ) signalling 70 . Identification of a host TMAO receptor is a strong possibility, given that structurally similar TMA has been shown to be a high-affinity agonist for a cell-surface G-protein-coupled receptor known as trace amine-associated receptor 5 (TAAR5) 81, 82 . In fact, there are now many examples of Nature Reviews | Microbiology . TMAO can then promote atherosclerosis, thrombosis, heart failure, insulin resistance and kidney disease via tissue-specific or cell-type-specific reprogramming. Through an unknown receptor-mediated sensing mechanism (indicated as 'TMAO sensor'), TMAO drives cell-specific signalling events that promote cardiovascular disease pathogenesis. In platelets, TMAO rapidly enhances stimulus-induced calcium (Ca
2+
) release, which signals to drive prothrombotic programmes. In endothelial cells (ECs) and smooth muscle cells (SMCs), TMAO rapidly activates mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to promote the expression of adhesion molecules such as intracellular adhesion molecule and E-selectin. In addition, TMAO can signal through currently unidentified pathways to regulate increased macrophage foam cell formation. TMAO can also initiate profibrotic programmes in the heart and kidney via a transforming growth factor-β (TGFβ)-phospho-SMAD3 (P-SMAD3) signalling axis. Collectively, these cellular events converge to promote atherosclerosis, thrombotic vascular disease and associated renal impairment. P-ERK1/2, phosphorylated extracellular-signal-regulated kinases 1 and 2; P-p38MAPK, phosphorylated p38 MAPK; P-p65, phosphorylated p65. dedicated host receptor systems for metabolites originating from gut microorganisms [48] [49] [50] [51] . Identification of a dedicated TMAO receptor would have broad implications given the clear links of TMAO in human disease. It is tempting to speculate that TMAO receptor antagonists could be an effective therapeutic strategy to prevent or even treat established CVD.
As TMAO pathway drug discovery efforts advance, it will be imperative to understand the microbial taxa responsible for regulating flux through the TMA-TMAO pathway. For example, very little is known regarding which species or broader communities are the main producers of TMA in mouse and human ecosystems. In mouse studies in which dietary source nutrients for TMAO were specifically altered (for example, dietary provision of choline, l-carnitine or γ-butyrobetaine), a refined list of taxa has been associated with circulating TMAO levels, including the broad order of RF39 (r = 0.49; false discovery rate (FDR) = 0.04); the families of Erysipelotrichaceae . Follow-up studies in humans comparing vegetarians and omnivores showed that several taxa of faecal microorganisms are associated with circulating TMAO levels, including Prevotella, Clostridiales Family XI Incertae Sedis, Peptostreptococcaceae, Clostridium, Fusibacter, Lachnospira and Sporobacter
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. Such associations between bacterial taxa and circulating TMAO levels are useful only in hypothesis generation, but they do not establish a direct link between the taxa and TMAO production. A more fruitful method of identifying bona fide TMA-producing bacterial species is to screen reference genomes to identify the genetic potential to generate TMA (for example, the presence of TMA lyase enzyme operons that encode CutC/D, CntA/B and YeaW/X), followed by functional studies. An elegant example of such reference genome mining was recently described 83 , supporting the power of genetics in predicting relevant metabolite-producing bacterial taxa. However, in regard to metabolite production, it is ultimately key to prove quantifiable biochemical potential. Coupling brute-force microbial culture with biochemistry, a recent study screened 79 culturable human commensal bacteria for the potential to produce TMA from choline in vitro 84 . This important study identified eight distinct bacterial strains with the biochemical capa city to produce TMA from choline, including Anaerococcus hydrogenalis, Clostridium asparagi forme, Clostridium hathewayi, Clostridium sporogenes, Edwardsiella tarda, Escherichia fergusonii, Proteus penneri and Providencia rettgeri 84 . More importantly, low-level colonization with a TMA producer (C. sporogenes) in the defined background of a core community that lacked TMA lyase activity (Collinsella aerofaciens, Bacteroides caccae, Bacteroides ovatus, Bacteroides thetaiotaomicron and Eubacterium rectale) resulted in both TMA and TMAO generation in vivo in recolonized gnotobiotic mice as well as reductions in choline levels in the host 84 .
Another recent study found that the choline utilization cluster (Cut) is widely distributed across many gut microbial phyla in human stool metagenomes 85 . In addition to human stool meta genomes, CutC can be found with similar frequency in oral mucosa and supragingival plaque 86 , making it tempting to speculate that oral TMA production may be associated with the link between periodontal disease and CVD risk. Finally, a recent study has identified the human gut microbial taxa possessing the choline TMA lyase (CutC) and the carnitine oxygenase (CntA) with the use of a multilevel screening approach 87 . Therefore, there has been rapid growth in our understanding surrounding which human commensals have the capacity to produce TMA from major source nutrients.
In addition to TMA-producing bacteria, there is also mounting evidence that certain microbial species can metabolize TMAO and TMA for maintenance of trophic chains in both colonic and marine bacterial ecosystems [88] [89] [90] [91] , but the relevant microorganisms and operons involved are still being elucidated. One major pathway facilitating catabolism of TMAO is driven by the bacterial torCAD operon, which encodes a TMAO reductase (TorA), a c-type cytochrome (TorC) and a TorA-specific chaperone (TorD) 88 . Additionally, bacteria present in marine ecosystems can also degrade TMAO through a TMAO demethylase enzyme (Tdm) 89 . Certain marine bacteria from the Roseobacter clade can use both TMA and TMAO as energy sources, which is facilitated by importing these metabolites via an ATP-binding cassette transporter, TmoXWV, for subsequent catabolism [89] [90] [91] . Certain methanogenic bacteria present in the human colonic ecosystem, such as Methanomassiliicoccus luminyensis, can reduce TMA as a substrate for methanogenesis 92 . It remains possible that these bacterial TMA-TMAO catabolic pathways are another potential avenue of therapeutic intervention and could be an ideal probiotic strategy. Identification
Box 1 | Therapeutic strategies
The majority of microbiome drug discovery efforts tend to focus on prebiotic or probiotic approaches because the causative mediators and microbial species involved in disease pathogenesis remain to be determined for most host phenotypes under investigation. Given the mounting evidence linking the microorganismdependent metabolite trimethylamine-N-oxide (TMAO) to cardiovascular disease (CVD) pathogenesis, there is a strong likelihood that the TMAO pathway will be one of the first microbial pathways selectively targeted with nonlethal small molecules for the amelioration of human CVD. In strong support of this, a recent study showed the first proof-of-concept studies employing a smallmolecule inhibitor of gut microbial trimethylamine (TMA) lyase enzymes that led to a reduction in TMA and TMAO levels and protection of mice against diet-induced atherosclerosis 58 . Regardless of which therapeutic approach is taken, because of the numerous mechanistic links between TMAO and the pathogenesis of disease as well as strong corroborative associations from multiple human clinical studies, the gut microbial TMAO pathway holds tremendous potential as a therapeutic target for CVD treatment and prevention.
Transient ischaemic attack
A brief episode of neurological dysfunction caused by lack of blood flow to the brain; also called a 'mini-stroke' .
of human gut commensals that catabolize TMA will be of particular interest for a potential probiotic.
Although the vast majority of studies support a mechanistic link between the TMAO pathway and CVD, it is important to note that not all studies have shown a clear association between dietary intake of TMAO source nutrients (choline or carnitine) and CVD risk [93] [94] [95] [96] [97] [98] [99] . One recent study showed that dietary l-carnitine supplementation, which modestly raised circulating TMAO levels, was associated with an ~15% decrease in aortic atherosclerotic lesion area without altering aortic cholesterol content in Apoe −/− mice transgenically expressing human cholesteryl ester transfer protein 93 . Furthermore, a large (n = 29,079) population study in Japan demonstrated that dietary choline and betaine intake, estimated by a semiquantitative food questionnaire, was not associated with CVD mortality 94 . Likewise, in the large (n = 14,430) American-based Atherosclerosis Risk in Communities (ARIC) study, it was found that dietary choline intake was not significantly associated with CVD 95 . In agreement, a large (n = 16,165) Dutch study showed that dietary intake of choline or betaine was not associated with CVD risk 96 . Unfortunately, none of these large population studies examining the relationship between dietary choline, betaine or carnitine intake and CVD outcomes measured circulating TMAO levels. Therefore, additional studies are needed to determine whether TMAO itself correlates with CVD risk in these same large population studies. This is likely to be the case given that a recent large (n = 19,256) meta-analysis of hard CVD end point studies showed that circulating TMAO levels were a much stronger predictor of major adverse cardiovascular events than the source nutrients of TMAO (choline, betaine and l-carnitine) 97 . Although the association between circulating TMAO levels and major adverse cardiovascular events is highly reproducible, some studies have suggested that this association is driven in part by impaired kidney function 98 . Also, a recent study showed that TMAO levels may not be equally associated with all types of vascular disease, especially in the case of large-artery ischaemic stroke and transient ischaemic attack 99 . Collectively, although most studies suggest a strong association between TMAO levels and atherosclerotic coronary heart disease, these recent findings suggest that additional work is needed to understand which patient populations would benefit from TMAO-lowering therapeutic strategies.
SCFAs and other fermentation products in cardiovascular disease pathogenesis. The products of gut microbial fermentation are by far the most well-studied gut microbial metabolites, having key roles both in the maintenance of gut microbial ecology and in finetuning host immunity and metabolic disease 21,100-103 . The major products of microbial fermentation of dietary fibres are SCFAs, with the most abundant metabolites being acetate, butyrate and propionate. Although additional studies are needed to identify the most abundant human commensal producers, some information is available regarding which taxa are responsible for the majority of SCFA production. Acetate is produced by a large number of enteric bacteria, with major contributors such as Ruminococcus spp., Prevotella spp., Bifidobacterium spp., Bacteroides spp., A. muciniphila, Blautia hydrogenotrophica, Clostridium spp. and Streptococcus spp. 104, 105 . Propionate can be generated via three distinct biochemical pathways from Bacteroides spp., Phascolarctobacterium succinatutens, Dialister spp., Veillonella spp., Megasphaera elsdenii, Coprococcus catus, Salmonella spp., Roseburia inulinivorans and Blautia obeum 104, 106 . Butyrate can be generated from the locally generated acetate substrate by Coprococcus comes, C. catus, Coprococcus eutactus, Anaerostipes spp., E. rectale, Eubacterium hallii, Faecalibacterium prausnitzii and Roseburia spp. 104, 106 . Butyrate can also be generated via carbohydrate fermentation by several members of the Lachnospiraceae, Ruminococcaceae and Acidaminococcaceae families 107 . Undoubtedly, the major drivers of SCFA production in both human and rodent gut microbiomes are not completely understood, and reference genomes predict that many additional SCFA producers are yet to be discovered. SCFAs can function as a macronutrient energy source and as hormone-like signalling molecules that enter the portal circulation to ultimately signal through dedicated host receptor systems to regulate innate immunity and host metabolism. Some of the currently identified host SCFA receptors include G-protein-coupled receptor 41 (GPR41; also known as free fatty acid receptor 3 (FFAR3)) 108 , G-protein-coupled receptor 43 (GPR43; also known as free fatty acid receptor 2 (FFAR2)) 108 , G-protein-coupled receptor 109A (GPR109A; also known as hydroxy carboxylic acid receptor 2 (HCAR2)) 109 and olfactory receptor 78 (Olfr78) 110 (see below). Although SCFAs are the most well-studied gut microorganism-derived metabolites, it is still unclear whether SCFAs are causally linked to the development of human diseases, especially CVD, and their manipulation to modulate disease processes and susceptibility remains under investigation. The vast majority of literature linking the gut microbiota to human disease implicates SCFAs as potential disease-preventing or disease-mitigating factors in obesity, diabetes, intestinal immunity, hypertension, kidney disease, cancer and both alcoholic and nonalcoholic fatty liver disease 21, [100] [101] [102] [103] . Although there is a substantial body of literature linking microorganism-derived SCFAs to CVD risk factors, there is a paucity of studies showing clear association with circulating SCFAs and CVD risk or mortality in humans. In fact, most of the links between SCFAs and CVD risk factors such as obesity, diabetes, hypertension, renal dysfunction and liver disease have been established in animal models. Therefore, unlike TMAO, the potential for SCFAs to be a therapeutic target for CVD is not strongly supported by independently replicated clinical studies. Gut microorganism-derived SCFAs and their links to metabolic disease in animal models have been recently covered in several excellent reviews 21, [100] [101] [102] [103] . Therefore, we highlight below only several SCFA intervention human trials, and we discuss recent results from studies using animal models.
In one of the first direct administration studies in humans, physiologically relevant doses of acetate or 
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A major sulfur-containing amino acid.
propionate were given to examine acute effects on metabolism 111 . This study found no effect on the levels of blood glucose or insulin, but both SCFAs reduced the levels of circulating free fatty acids 111 . Moreover, independent studies showed that although acute (3-hour) gastric infusion of SCFAs had no effect on glycaemia, the levels of free fatty acid were reduced 112 . Follow-up studies demonstrated that SCFA administration increased serum glucagon levels, which may have indirectly altered the levels of circulating free fatty acid 113 . In a subsequent long-term study in which propionate was supplemented for 7 weeks, there was a modest decrease in fasting glucose and alterations in glucose-stimulated insulin secretion during an oral glucose tolerance test 114 . Furthermore, provision of dietary supplementation of nondigestible polysaccharides yielded contradicting results [115] [116] [117] [118] [119] [120] [121] . However, it is important to note that although these studies often claim that the observed metabolic effects are driven by alterations in the levels of SCFAs, fibre-rich diets have pleotropic effects that extend beyond SCFA biology. Recently, one of the first randomized, double-blind, placebo-controlled antibiotic trials was conducted in which the levels of SCFAs and a number of metabolic parameters were carefully monitored 122 . As expected, the antibiotic (vancomycin) treatment group showed drug-selective reorganization of gut microbial diversity and composition, which was associated with statistically significant reductions in the levels of SCFAs 122 . Surprisingly, even with large effects on the levels of SCFAs, there were no apparent alterations in energy or glucose homeostasis, which indicates that the phenotypic effects of SCFAs seen in mice are not so easily translated into humans 122 . Collectively, these studies highlight the critical need for additional clinical investigation into whether modulation of SCFAs would hold any benefit in patients with CVD.
Even with these seemingly negative results in humans, there are some emerging discoveries with SCFAs and other microbial fermentation products that deserve additional investigation. For instance, a recent report described a pathway by which SCFAs can engage the olfactory receptor Olfr78 and GPR41 in the kidney to regulate renin secretion and blood pressure 97 . Furthermore, another study demonstrated that obstructive sleep-apnoea-induced hypertension is transmissible by gut microbial transplantation 123 . In addition to SCFAs, the gut microbial fermentation product lactic acid has been reported to activate the host G-proteincoupled receptor 81 (GPR81; also known as hydrocarboxylic acid receptor 1 (HCAR1)) to suppress adipose tissue lipolysis 124 . Interestingly, inhibition of the lactate receptor GRP81 was shown to protect against ischaemic brain injury in mice 125 . As noted above, another emerging biologically active non-SCFA bacterial fermentation product is succinate [126] [127] [128] . Succinate is produced in large quantities in mammalian cells during the citric acid cycle, but it can also be generated by colonic microorganisms, including Prevotella 128 . Prevotellagenerated succinate is presumed to be responsible for the observed beneficial effect on mouse intestinal glucose production following provision of Prevotella copri 128 .
Succinate can activate the host G protein-coupled receptor 91 (GPR91; also known as succinate receptor 1 (SUCNR1)) , which indicates a potential new gut microbial metabolite-host receptor interaction that is relevant to CVD pathogenesis. With the exception of the butyrate receptor GPR109A 129 , there have been no studies showing that SCFA, lactate or succinate receptor knockout mice exhibit alterations in atherosclerosis susceptibility; therefore, additional preclinical studies are needed.
The gut microbial bile acid metabolome in cardiovascular disease. Gut microbial metabolism of bile acids represents one of the more intriguing stories of metaorganismal symbiosis, whereby an intimate bidirectional circuit produces essential detergents for intestinal fat absorption in the host and provides a host-derived signal to maintain microbiome community structure [130] [131] [132] . Bile acids are now recognized to function as diverse signalling molecules that regulate host macronutrient metabolism and energy expenditure (FIG. 3) (reviewed in . Once delivered to the colonic microenvironment, bile salts can induce cytotoxic effects in certain members of the gut microbiome ecosystem [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] .
Although not completely understood, primary bile salts and locally produced secondary bile acids are thought to regulate microbial community structure via membrane detergent effects and by inducing DNA damage in certain members of microbial communities [140] [141] [142] [143] . Interestingly, certain bacteria have evolved bile salt resistance mechanisms via alterations in efflux pumps 140, 141 and alterations in membrane lipid and protein composition [142] [143] [144] [145] [146] . For example, Bifidobacterium longum subsp. longum BBMN68 possesses a haemolysin-like protein that enables selective resistance to taurine-conjugated bile salts 144 . Some bacteria such as Campylobacter spp. and Salmonella enterica subsp. enterica serovar Typhimurium can be readily detected in gall-bladder bile, where bile acid concentrations are extremely high 147 . The ability of bile salts and bile acids to dictate gut microbiome community structure likely has a major role in downstream effects on host metabolism.
The microorganisms that are able to persist in the bilesalt-rich colonic microenvironment can then chemically diversify bile salts into a number of biologi cally active species that can be sensed by the host. One of the best-studied microorganism-driven biotransformations is the enzymatic hydrolysis of the C24 N-acyl bond of glycine-conjugated or taurine-conjugated bile salts into free bile acids by bile salt hydrolase (BSH) [134] [135] [136] [137] . BSH activity is widespread through both Gram-positive and Gram-negative species, including Clostridium, Bifidobacterium, Enterococcus, Lactobacillus, Bacteroides, Methanobrevibacter smithii, Methanosphera stadmanae and possibly many others [134] [135] [136] [137] . In addition to deconjugation, gut microorganisms are the sole source of 7α-dehydroxylase and 7β-dehydroxylase activity, which generates 'secondary' bile acids such as deoxycholic acid, lithocholic acid, hyodeoxycholic acid and ursodeoxycholic acid [133] [134] [135] . Unfortunately, there is currently limited information in regards to the bacteria genera that
Postprandial state
The state immediately following a meal.
possess 7α-dehydroxylase and 7β-dehydroxylase activity, and additional studies are needed in this area. In fact, the vast majority of genetic and biochemical studies have focused primarily on substrain Clostridium scindens, in which the bile-acid-inducible (bai) operon has been well characterized 137 . In addition to deconjugation and 7α-dehydroxylase and 7β-dehydroxylase reactions, gut microorganisms can oxidize or epimerize bile acids via several distinct enzymes of the hydroxysteroid dehydro genase (HSDH) family 148, 149 . HSDH activity has been confirmed in a diverse variety of bacteria, including Bacteroides, Clostridium, Escherichia, Eggerthella, Eubacterium, Peptostreptococcus and Ruminococcus. Formation of ethyl esters and long-chain fatty acid esters from bile acids can be driven by gut bacteria such as Bacteroides, Eubacterium and Lactobacillus 150, 151 . However, the bacterial enzymes responsible for these esterification reactions are unknown. Finally, gut microorganisms can remove sulfate from either 3α-sulfated or 3β-sulfated bile acids, and this sulfatase activity has been seen in Clostridium, Peptococcus, Fusobacterium and Pseudomonas 152 . Collectively, through deconjugation, oxidation, epimerization, 7α-dehydroxylation, 7β-dehydroxylation, esterification and desulfation, gut micro organisms chemically diversify the bile acid pool, and then the secondary bile acids can enter the portal circulation to function as endocrine-like signalling molecules with potent effects on host physiology and disease.
Once bacterially modified bile acids enter the portal blood, typically in the postprandial state, they can engage in an ever-growing number of recognized host bile acid receptors (FIG. 3) . The best-known host bile acid receptor is FXR (farnesoid X-activated receptor; also known as NR1H4), which regulates the transcription of key genes involved in primary bile acid biosynthesis 153 . Importantly, polymorphisms in FXR have been linked with hyperglycaemia and circulating free fatty acid levels 154 , and genetic deletion of Fxr in mice alters the progression of athero sclerosis 155 . Recent studies have also shown that FXR is required for the metabolic reprogramming initiated by human microbial transplantation 156, 157 . Interestingly, transplantation of human microbiota into conventional mice can alter mouse bile acid composition and induce FXR activation by reducing the levels of the FXR antagonist tauro-β-muricholic acid 157 . Another host bile acid receptor gaining attention in recent years is the G-protein-coupled bile acid receptor 1 (GPBAR1; also known as TGR5) 158, 159 . TGR5 activation has been linked to increased energy expenditure 145 , and TGR5-knockout mice are protected against atherosclerosis development 158 . Secondary bile acids such as lithocholic acid can activate the nuclear hormone receptor pregnane X receptor (PXR; also known as nuclear receptor subfamily 1 group I member 2 (NR1I2)), which is a well-known transcriptional regulator of xenobiotic and lipid metabolism 160 . Genetic deletion of the lithocholic acid receptor PXR in mice reduces the progression of athero sclerosis 161 . Interestingly, certain bacterially modified bile acids (3-oxo-lithocholic acid and lithocholic acid) can also activate the vitamin D3 receptor (VDR) 162 , and genetic studies in both humans and mice have shown a role for VDR activation in CVD-related disease [162] [163] [164] . Taurine-conjugated bile acids have been shown to activate specific muscarinic receptors 165 , and poly morphisms in the muscarinic acetylcholine receptor M2 isoform have recently been associated with reduced Nature Reviews | Microbiology Initially, primary bile acids are synthesized in the host liver from cholesterol. De novo synthesized primary bile acids such as cholic acid, chenodeoxycholic acid and muricholic acid (produced only in rodents) are then conjugated with either glycine (humans) or taurine (humans and mice) at the C24 carboxyl position. Following conjugation, the resulting bile salts are secreted into bile along with cholesterol and phospholipids to form mixed micelles, which are transiently stored in the gall bladder. When a meal is ingested, the gall bladder contracts to release mixed micelles into the proximal intestine, where they function as essential emulsifiers to enable proper absorption of hydrophobic molecules such as fatty acids and fat-soluble vitamins (such as vitamins A, D, E and K) (not shown). Importantly, bile salts are left behind in the intestinal lumen, where they ultimately traverse to the colon. Once in the colonic microenvironment, they participate in a bidirectional interplay regulating the microbial community structure, and they are involved in the subsequent microorganism-driven metabolism of primary bile salts into secondary bile acids (deoxycholic acid and lithocholic acid), which can have an impact on host physiology and disease susceptibility. Importantly, after aiding in intestinal lipid absorption, both primary bile salts and secondary bacterial metabolites are almost quantitatively reabsorbed (>95% recovered) in the ileum via dedicated host transporters in ileal enterocytes (not shown). This reabsorptive process provides newly diversified bile acid species, which can then signal to the host through dedicated receptor systems, including farnesoid X-activated receptor (FXR), G-protein-coupled bile acid receptor 1 (TGR5), pregnane X receptor (PXR), vitamin D3 receptor (VDR), muscarinic acetylcholine receptors M2 and M3 (M2 and M3, respectively), and sphingosine 1-phosphate receptor 2 (S1PR2). CVD, cardiovascular disease.
heart rate and death by myocardial infarction 166 . Finally, all conjugated bile acids can activate signalling through the sphingosine-1-phosphate receptor 2 (S1PR2) 167 , and S1PR2-knockout mice have been shown to have reduced atherosclerosis burden in the apolipoprotein-E-deficient background 168 . Collectively, microorganism-derived bile acid metabolites represent diverse endocrine signals that hold tremendous therapeutic potential. In fact, in May 2016, a semisynthetic bile acid analogue, obeticholic acid (Ocaliva; Intercept Pharmaceuticals, Inc.) was approved by the FDA for the treatment of liver disease 169 . This success story is likely one of many to come at the microbial metabolite-host receptor interface.
Conclusions
Although drug discovery has historically focused on targeting human enzymes, we are entering a new era of microbial pharmacology as biomedical research is aiming to target the microorganisms that live within us to improve human health. In particular, CVD is uniquely positioned for success, with several gut microbial metabolites clearly associated with CVD risk. Successes in drug discovery at the microbial metabolite-host receptor interface have already been realized, and preclinical proof of concept is now established for nonlethal small-molecule inhibitors of TMAO production 58 . In parallel, there are substantial efforts to develop prebiotic, probiotic and faecal transplantation strategies to interrupt microorganism-host pathways that are involved in CVD pathogenesis 51 . As we forge ahead to determine microbial contributions to the origin and progression of human diseases, it is imperative that we move away from the traditional microbiome profiling approaches that simply ask what is there. Instead, we need to ask what disease-causing microbial products can be identified. Once we identify relevant microorganism-derived molecules, we must adopt classic principles of endocrinology to identify the host receptor systems involved in disease pathogenesis. The diversity of chemicals and metabolites derived from our gut microbial symbionts is quite astounding and provides an essentially untapped source of new drug targets for cardiometabolic disease.
